Table 1.
Female Patients with Inflammatory Breast Cancer, National Cancer Data Base, 2010–2015
| All Patients | cN0 | cN1 | cN2–3 | ||
|---|---|---|---|---|---|
| N=3,471 (100%) | N=597 (17.2%) | N=1,833 (52.8%) | N=1,041 (30.0%) | P-Value | |
| Age | |||||
| Median (IQR) | 56 (47 – 64) | 58 (49 – 66) | 55 (47 – 63) | 56 (48 – 64) | <0.001 |
| Race/Ethnicity | |||||
| Hispanic | 246 (7.1%) | 32 (5.4%) | 127 (6.9%) | 87 (8.4%) | <0.001 |
| Non-Hispanic Black | 543 (15.6%) | 80 (13.4%) | 263 (14.3%) | 200 (19.2%) | |
| Non-Hispanic Other | 91 (2.6%) | 18 (3%) | 44 (2.4%) | 29 (2.8%) | |
| Non-Hispanic White | 2463 (71%) | 437 (73.2%) | 1339 (73%) | 687 (66%) | |
| Histology | |||||
| Ductal | 2,301 (66.3%) | 366 (61.3%) | 1,260 (68.7%) | 675 (64.8%) | 0.005 |
| Lobular | 115 (3.3%) | 34 (5.7%) | 50 (2.7%) | 31 (3%) | |
| Mammary | 110 (3.2%) | 23 (3.9%) | 58 (3.2%) | 29 (2.8%) | |
| Metaplastic | 26 (0.7%) | 5 (0.8%) | 11 (0.6%) | 10 (1%) | |
| Missing | 78 (2.2%) | 17 (2.8%) | 40 (2.2%) | 21 (2%) | |
| Other/NOS* | 841 (24.2%) | 152 (25.5%) | 414 (22.6%) | 275 (26.4%) | |
| Grade | |||||
| Unknown | 415 (12%) | 70 (11.7%) | 209 (11.4%) | 136 (13.1%) | <0.001 |
| 1 | 93 (2.7%) | 31 (5.2%) | 36 (2%) | 26 (2.5%) | |
| 2 | 934 (26.9%) | 202 (33.8%) | 518 (28.3%) | 214 (20.6%) | |
| 3 | 2029 (58.5%) | 294 (49.2%) | 1070 (58.4%) | 665 (63.9%) | |
| Receptor Subtype | |||||
| HR+/HER2+ | 586 (16.9%) | 93 (15.6%) | 343 (18.7%) | 150 (14.4%) | 0.005 |
| HR+/HER2− | 1308 (37.7%) | 254 (42.5%) | 665 (36.3%) | 389 (37.4%) | |
| HR−/HER2+ | 598 (17.2%) | 88 (14.7%) | 324 (17.7%) | 186 (17.9%) | |
| TNBC | 892 (25.7%) | 138 (23.1%) | 466 (25.4%) | 288 (27.7%) | |
| Surgery Type | |||||
| Lumpectomy | 75 (2.2%) | 19 (3.2%) | 35 (1.9%) | 21 (2%) | 0.17 |
| Mastectomy | 3396 (97.8%) | 578 (96.8%) | 1798 (98.1%) | 1020 (98%) | |
| LNs Examined | |||||
| Median (IQR) | 11 (7 – 17) | 10 (5 – 15) | 12 (7 – 17) | 12 (7 – 17) | <0.001 |
| Positive LNs | |||||
| Median (IQR) | 4 (2 – 9) | 4 (2 – 8) | 4 (1 – 8) | 6 (2 – 10) | <0.001 |
| Axillary Surgery Extent | |||||
| ≤9 LNs | 1350 (38.9%) | 288 (48.2%) | 674 (36.8%) | 388 (37.3%) | <0.001 |
| ≥10 LNs | 2121 (61.1%) | 309 (51.8%) | 1159 (63.2%) | 653 (62.7%) | |
| Received Endocrine Therapy (HR+ patients only, n=1929 – cN0: 357, cN1: 1020, cN2–3: 552) | |||||
| No | 233 (12.1%) | 47 (13.2%) | 112 (11%) | 74 (13.4%) | 0.22 |
| Yes | 1613 (83.6%) | 288 (80.7%) | 868 (85.1%) | 457 (82.8%) | |
| Received Radiation Therapy | |||||
| No | 543 (15.6%) | 125 (20.9%) | 252 (13.7%) | 166 (15.9%) | <0.001 |
| Yes | 2921 (84.2%) | 471 (78.9%) | 1578 (86.1%) | 872 (83.8%) | |
| Pathological T Classification | |||||
| ypT0 | 693 (20%) | 103 (17.3%) | 384 (20.9%) | 206 (19.8%) | 0.012 |
| ypT1 | 1035 (29.8%) | 184 (30.8%) | 571 (31.2%) | 280 (26.9%) | |
| ypT2 | 461 (13.3%) | 78 (13.1%) | 250 (13.6%) | 133 (12.8%) | |
| ypT3 | 341 (9.8%) | 53 (8.9%) | 182 (9.9%) | 106 (10.2%) | |
| ypT4 | 941 (27.1%) | 179 (30%) | 446 (24.3%) | 316 (30.4%) | |
| Pathological N Classification | |||||
| ypN0 | 1211 (34.9%) | 298 (49.9%) | 630 (34.4%) | 283 (27.2%) | <0.001 |
| ypN1 | 914 (26.3%) | 138 (23.1%) | 573 (31.3%) | 203 (19.5%) | |
| ypN1mic (subset of ypN1) | 145 (4.2%) | 26 (4.4%) | 87 (4.7%) | 32 (3.1%) | |
| ypN2 | 857 (24.7%) | 116 (19.4%) | 407 (22.2%) | 334 (32.1%) | |
| ypN3 | 489 (14.1%) | 45 (7.5%) | 223 (12.2%) | 221 (21.2%) | |
*
includes 691 patients for whom “inflammatory breast carcinoma” was only histological information provided